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Inflammation is a highly dynamic and complex adaptive process to preserve and restore tissue
homeostasis. Originally viewed as an immune-privileged organ, the central nervous system (CNS) is
now recognized to have a constant interplay with the innate and the adaptive immune systems,
where resident microglia and infiltrating immune cells from the periphery have important roles.
Common diseases of the CNS, such as stroke, multiple sclerosis (MS), and neurodegeneration, elicit
a neuroinflammatory response with the goal to limit the extent of the disease and to support repair
and regeneration. However, various disease mechanisms lead to neuroinflammation (NI) contribut-
ing to the disease process itself. Molecular imaging is the method of choice to try to decipher key
aspects of the dynamic interplay of various inducers, sensors, transducers, and effectors of the
orchestrated inflammatory response in vivo in animal models and patients. Here, we review
the basic principles of NI with emphasis on microglia and common neurologic disease mechanisms,
the molecular targets which are being used and explored for imaging, and molecular imaging of
NI in frequent neurologic diseases, such as stroke, MS, neurodegeneration, epilepsy, encephalitis,
and gliomas.
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Introduction
Present in all vertebrates, inflammation is a highly
dynamic and complex process combining local and
systemic reactions of multiple cell types, chemical
signals, and signaling pathways. Inflammation is an
adaptive response for restoring tissue homeostasis
(Medzhitov, 2008) and implies a tight interplay
between the tissue and the immune system. It is
found in physiological and pathological situations,
where it is beneficial when it contributes to support
repair and regeneration (e.g., wound healing, scar
formation, and suppression of infection) and, on the
opposite, detrimental when excessive or persistent
inflammation worsens tissue injury (e.g., allergy,
chronic infections, and neurodegeneration).
Almost any type of tissue insult activates inflam-
mation; however, the inflammatory response varies
with the nature of the insult (mechanical, chemical,
infectious, and tumoral) and with the tissue. Origin-
ally viewed as an immune-privileged organ, the CNS
was progressively recognized to be constantly in
direct and dynamic interaction with the innate and
the adaptive immune systems. Neuroinflammation
(NI) is particular because (1) the CNS has efficient
natural protection from mechanical aggressions by
the skull and from biological and chemical aggres-
sions by the blood–brain barrier (BBB); (2) the CNS
has limited regeneration capacities; and (3) any local
impairment of its spatial organization can lead to the
definitive loss of a major function. Neuroinflamma-
tion is a physiological defense process in which
resident microglia and infiltrating immune cells from
the periphery have an important role, but it is also
involved during brain maturation and neurogenesis.
Diseases of the central nervous system (CNS) lead to
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a neuroinflammatory response, whose trivial goal is
to limit the extent of the disease, to clear tissue
damage and to support repair and regeneration.
However, there is also clear evidence in several
cases that NI may, depending on the inducing
pathological mechanism, contribute to the disease
process itself. More surprisingly, NI seems also to be
associated with psychiatric disorders such as major
depression (Alexopoulos and Morimoto, 2011) or
schizophrenia (Doorduin et al, 2009a).
Given the dynamic nature of NI, the variety of cells
and factors involved and the changes in tissue
organization induced, exploration methods of prac-
tical value for its understanding must take ‘time’ and
‘space’ into account. In many instances, anatomical
and functional in-vivo imaging methods are essential
for diagnosis and as read-out of effective therapy and
have a major impact on patient care. More recently,
in-vivo imaging technologies have matured
enough to look into the molecular mechanisms and
functional consequences of neuroinflammatory
processes at various disease stages, and even though
we are still struggling through the ‘jungle’ of
chemical effectors, receptors, signaling mechanisms,
and cellular interactions involved, in-vivo cellular
and molecular imaging is increasingly called on to
improve our understanding of NI. Conversely, the
objective of molecular imaging is not only to
decipher further the cellular biochemistry of NI,
but also to develop efficient, reliable, and quantita-
tive noninvasive methods capable to guide thera-
peutic developments that alter neuroinflammatory
cascades, prevent tissue damage and support tissue
repair processes. At the same time, care must be
taken not to overemphasize the clinical importance
of NI during the disease process, just because
imaging studies provide evidence of its presence,
which even though genuine may have little practical
importance. Future work should therefore concen-
trate on the dynamic interplay between NI and the
molecular mechanisms inducing cellular damage.
The intention of this article is to review NI imaging
strategies which have been used in experimental and
clinical applications. Rather than focusing on a
single target, imaging method, or disease mechanism,
we describe and discuss the current status and
possible future developments of (1) molecular targets
for NI, (2) imaging methods and technologies, in
(3) a variety of neurologic diseases. This review shall
complement other reviews that guide the reader
through the advantages and disadvantages of a
particular imaging modality (e.g., Stoll and Bend-
szus, 2010 and Wunder et al, 2009). Instead, we
focus on molecular mechanisms and possible targets
for imaging in various neurologic diseases, assuming
that the reader is familiar with the basic principles of
the major imaging technologies, such as optical,
radionuclide (positron-emission tomography (PET),
and single-photon emission computed tomography
(SPECT)), and magnetic resonance imaging (MRI),
as their different strengths and weaknesses have
already been extensively commented upon, i.e., a
high sensitivity and high spatial resolution for
optical; high sensitivity and possibility for true
signal quantification for radionuclide imaging; and
high spatial resolution and physiological and bio-
chemical imaging for MRI.
The review is divided into a first part, in which the
basic principles of NI are grossly summarized with
special emphasis on microglia. In the second part,
several molecular targets among the complex inter-
play between inducers, transducers, and effectors of
NI are selected and discussed, in particular those
which are candidates to or are already used as targets
for noninvasive molecular imaging. The third part
deals with clinical and experimental molecular
imaging of NI in the most frequent neurologic diseases
(stroke, multiple sclerosis (MS), neurodegenerative
diseases (ND), epilepsy, encephalitis, and gliomas).
Basic principles of neuroinflammation
The term ‘inflammation’ refers to a generic multi-
cellular process, characterized by (1) changes in local
vasculature (increased blood flow and vascular
permeability), (2) activation of resident immune
competent cells, (3) infiltration of mobile cells of
the immune system (neutrophils, macrophages, and
lymphocytes), and (4) cytokine production (Graeber
et al, 2011). Neuroinflammation is the inflammation
of the nervous system observed in diseases of the
CNS, including stroke, MS, Alzheimer’s (AD) and
Parkinson’s disease (PD), neurotrophic viral infec-
tions, neoplasias, head traumas, and even excess
ethanol absorption. All these pathologies trigger an
immune activation of the brain, which contributes on
the one hand to tissue damage, loss of neurons and
dysfunction, on the other hand is involved in
neuroregeneration and tissue repair (Rivest, 2009).
Signals triggering inflammation may vary depending
on the cause or inducing factor. Using optical in
zebrafish, hydrogen peroxide (H2O2) was recently
identified as the very first signal for wound detection
and the primer of inflammation (Niethammer et al,
2009). It is not unlikely that H2O2 is also the signal
initiating NI in the mammalian brain, although this
remains to be demonstrated. Between the myriad of
primary and secondary signaling molecules involved
at different levels in NI, the role of ATP in triggering
the activation of microglia cells is well established
and was beautifully shown in live mouse brains by
two-photon microscopy (Davalos et al, 2005).
Neuroinflammation is classically associated with
CNS infections (e.g., herpes simplex virus type 1
(HSV-1) encephalitis) and autoimmune disease (e.g.,
MS) as well as with acute (e.g., ischemia) or chronic
(e.g., AD) CNS disease processes. The NI occurring in
the absence of microorganisms has been termed as
sterile inflammation (Chen and Nunez, 2010). In
chronic CNS diseases, such as AD and PD, some
authors have proposed to replace the term ‘neuroin-
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flammation’ with the term ‘microglial activation’
(Graeber et al, 2011) with respect to the leading role
of microglia and the absence of an obvious participa-
tion of granulocytes or T cells in these diseases.
Neuroinflammation can be viewed as the immune
response of the brain, a symphony played by an
orchestra of many cells and molecules and involving
an intricate combination of events with varying time
courses:
(1) Activation of damage-associated molecular pat-
terns (DAMPs; e.g., high-mobility group box 1
proteins, heat-shock proteins, histones, oxidized
lipids, ATP, amyloid-b (Ab)) by tissue injury, or of
pathogen-associated molecular patterns by exo-
genous pathogens;
(2) Activation of Toll-like receptors (TLRs) of various
subtypes and of the receptor for advanced
glycation end products with subsequent release
of adhesion molecules, cytokines, and chemokines
directing activation and targeted migration of effec-
tor cells (microglia, macrophages, and lymphocytes);
(3) Activation and recruitment of microglial cells,
the major cell of innate immunity in the brain;
(4) Infiltration of macrophages and T lymphocytes of
various subtypes (Th1, Th2, Th17, and regulatory
T cells);
(5) Alteration of the BBB that is designed to prevent
entry of T cells and neurotoxic compounds at the
neurovascular unit;
(6) Activation and recruitment of astrocytes that tend
to control T-cell infiltration into the CNS by
inducing apoptosis;
(7) Release or expression of a variety of signaling
factors, including the neuron-derived neuropep-
tides, membrane proteins (e.g., fractalkine (FKN),
cannabinoid receptors, and major histocompat-
ibility complex molecules), semaphorins and
lectins that all take part in the regulation of the
neuroinflammatory process (reviewed by Amor
et al, 2010; Macrez et al, 2011; Neumann et al,
2009; and Tian et al, 2009; Figure 1).
The main actors of the innate (nonspecific) immune
response of the CNS are the microglial cells that
constitute B10% of the entire cell population of the
brain. Microglia represent the brain’s resident macro-
phages involved in the removal of cell debris after
ischemia or myelin damage, in the limitation of
neurotrophic viral infections, as well as in neurorepair
processes. Microglia are stimulated by and contribute
to a variety of brain diseases (Perry et al, 2010) and,
depending on the injury and microenvironmental
conditions, may aggravate injury and cause neurode-
generation, or conversely may mediate protective
mechanisms promoting tissue repair and regeneration,
in opposing roles that have been termed as ‘the Yin
and Yang’ of microglia (Czeh et al, 2011). Microglia are
essential for normal brain maturation and involved in
various developmental processes such as apoptosis,
axonal growth and guidance, regulation of embryonic
cortical precursor cell development, neuronal differ-
entiation, astrocyte proliferation, and angiogenesis
(Czeh et al, 2011). In the adult brain under normal
physiological conditions, microglia exhibit a nonin-
flammatory phenotype often described as quiescent or
resting. However, imaging studies of fluorescently
tagged microglia have shown that, as ‘cops on the beat’
(Raivich, 2005), microglial cells exert active and
permanent surveillance of their local environment
and produce anti-inflammatory and neurotrophic
factors (Davalos et al, 2005; Nimmerjahn et al, 2005).
After activation by various stimuli (tissue damage,
pathogen invasion, and protein aggregates), microglia
switch to an activated phenotype and promote an
inflammatory response to serve pathogen clearance
and tissue repair (Davalos et al, 2005). Reactive
microglial cells derived from resident microglia have
morphological features similar to infiltrated macro-
phages derived from bone marrow (BMD). As the
main immune cells of the CNS, microglial cells come
in two major subtypes: parenchymal versus bone
marrow derived microglia cells with, respectively, low
and high major histocompatibility complex class II
expression, corresponding respectively to a poor or
high antigen-presenting function (Turrin and Rivest,
2006). A recent study suggests that bone marrow
derived cells do not enter the healthy CNS in the
adult animal and that microglia and blood-derived
monocytes have distinct embryonic origins: micro-
glia seed the CNS early during embryogenic devel-
opment while, thereafter, there is no significant
contribution from adult hematopoietic stem cells to
the resident pool of microglia in the normal brain
(Ginhoux et al, 2010).
The involvement of microglia in developmental
processes (apoptosis, axonal growth, and guidance)
may be related both to neurorepair mechanisms,
especially in the context of their ability to secrete
various growth factors, such as brain-derived neuro-
trophic factor, basic fibroblast growth factor, and
insulin-like growth factor (Czeh et al, 2011) and to
inflammation-related neurotoxicity. Indeed, several
inducers, sensors, transducers, and effectors seem to
contribute both to the orchestrated inflammatory
response and to the microglia-mediated neurotoxi-
city (Rivest, 2009) and expression of various surface
receptors, including those for complement, cyto-
kines, chemokines, major histocompatibility com-
plex II, and others, trigger or amplify the innate
immune response. The simplest, though schematic,
manner to describe microglial activation is to use the
similarity with the two macrophage types described
in peripheral inflammation. Depending on the mode
of activation and environmental factors such as age,
surveying microglia may come into two phenotypes:
the proinflammatory ‘M1’ phenotype is activated by
lipopolysaccharides and interferon-g and corre-
sponds to the ‘classical’ pathway of macrophage
activation, while the anti-inflammatory M2 pheno-
type is activated by interleukin (IL)-4 and IL-13
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through the ‘alternative’ pathway of macrophage
activation. M1-type microglia produce tumor necro-
sis factor-a, IL-1b, IL-6, nitric oxide, superoxide,
hydrogen peroxide, and matrix metalloproteinases.
The M1 microglia phenotype has a central role in
host defense against pathogens and tumor cells but
also triggers damage to healthy neurons (Czeh et al,
2011). In contrast, the anti-inflammatory M2 micro-
glia phenotype expresses IL-10 and arginase-1 and
promotes tissue remodeling/repair and angiogenesis
(Czeh et al, 2011). Such a classification in two
phenotypes is probably too schematic as the diver-
sity of microglial phenotypes that can be observed
in vivo is obviously larger (Olah et al, 2011). Among
open questions are (1) the nosology of intermediate
states between ‘surveying’ and ‘activated’ microglia
and the existence of ‘primed’ microglia (Ferrari and
Tarelli, 2011); (2) the molecular mechanisms respon-
sible for the switch between microglial phenotypes
(Parkhurst and Gan, 2010); and (3) the control
exerted by other cells on microglia activation or
deactivation. Concerning this latter point, astrocytes
have been claimed to modulate the levels of micro-
glial production and release of reactive oxygen
species (Min et al, 2006; Shih et al, 2006). The role
of microglia in neurogenesis and aging (reviewed in
detail by Gemma et al, 2010) pin-pointed out
important interactions between neuron-derived
FKN (also known as CX3CL1) and microglial expres-
sion of its receptor CX3C chemokine receptor 1 (also
known as FKN receptor) for the control of microglial
function. Disruption of this dialog triggers the
induction of an M1 microglia phenotype and a
subsequent increase in the expression of IL-1b and
TNF-a. Since aging is associated with a decrease in
FKN expression, FKN/CX3C chemokine receptor 1
signaling is disrupted in aged individuals and
this leads to an increase in microglial activation
and overexpression of proinflammatory cytokines
(Cardona et al, 2006; Gemma et al, 2010).
Figure 1 Components of the neurovascular unit (NVU), the ‘Vicious Cycle’ of neuroinflammation, and the ‘Ying and Yang’ of
microglia. In ischemic stroke and multiple sclerosis (MS) (A), peripheral immune cells contribute substantially to the local
inflammatory response and tissue damage. The dynamics of blood–brain barrier (BBB) penetration of immune cells is increasingly
being studied in vivo by two-photon microscopy at the cellular level and by ultrasmall superparamagnetic iron oxides (USPIOs)
(phagocytosed by peripheral macrophages) and magnetic resonance imaging (MRI). In neurodegenerative diseases (B), the BBB is
intact and neuroinflammation (NI) is predominated by the activation of microglia cells, which is mostly studied by translocator
protein (TSPO)-targeting tracers and positron-emission tomography (PET) or single-photon emission computed tomography (SPECT)
imaging. In Alzheimer’s disease (AD), for example, A forms aggregates that activate microglia through Toll-like receptor (TLR) and
receptor for advanced glycation end products (RAGE). Activated microglia secrete inflammatory mediators such as interleukin (IL)-6,
IL-1b, and tumor necrosis factor (TNF)-a to coactivate astrocytes and to induce neuronal death, which in turn will amplify microglia
activation through purinergic P2X7 receptors. Protective microglia mediate Ab clearance, removal of cell debris, and promote
neuroregeneration. It should be stated that the clear distinction between ‘surveying,’ ‘primed,’ and ‘activated’ microglia may be an
oversimplification of the complex molecular guidance of various microglia functional states. (Figure prepared according to Ferrari and
Tarelli, 2011; Glass et al, 2010; and Moskowitz et al, 2010.) COX-2, cyclooxygenase-2; AP-1, activator protein; NF-kB, nuclear
factor-kB; iNOS, nitric oxide synthase; ROS, reactive oxygen species; NO, nitric oxide; TGF-b, tumor growth factor-b.
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The rational design of molecular imaging targets
would greatly benefit from a more thorough under-
standing of the microglial phenotype–function rela-
tionships as discussed in Olah et al (2011). It seems
likely that future studies will help to better define
the different microglia populations, based both on
the nature of the stimulus that provokes the initial
insult and on subsequent secondary events that
influence the microglial phenotype, and that this
will help to understand the influence of microglial
phenotypes on the outcome of CNS injuries and
pathologies (Perry et al, 2010). Given our presently
limited knowledge of microglial dynamics, it may
appear simpler at this stage to distinguish between
the activated microglia found in acute inflammation
(mechanical brain damage, transient infections, and
stroke) and the chronically activated microglia found
in neurodegenerative disorders or chronic infections
(Parkhurst and Gan, 2010). However, practical
biomarkers have yet to be validated for an irrefutable
recognition of these two microglial states.
Molecular targets for imaging
neuroinflammation
All molecular imaging techniques, including two-/
multiphoton and fluorescence microscopy, PET,
SPECT, and MRI are used experimentally and clini-
cally to decipher molecular alterations of neurologic
disorders. Here we place the emphasis on the
molecular imaging targets directly or indirectly con-
nected to NI.
Damage-Associated Molecular Patterns/Pathogen-
Associated Molecular Patterns
A major recent breakthrough for in-vivo molecular
imaging of disease-specific molecular alterations has
been the direct visualization of amyloid-b (the DAMP
of AD) using thioflavine and multiphoton microscopy
(Bacskai et al, 2001). Direct assessment of the
amyloid plaque burden and the effect of immunomo-
dulatory therapy helped the development of radi-
olabeled thioflavine derivatives (e.g., Pittsburg
compound B; [11C]PIB) for imaging Ab in humans
(Klunk et al, 2004). Combined imaging of Ab and
microglial activation is given special attention in
patients with presymptomatic AD and mild cognitive
impairment (MCI), in the hope to answer the question
whether Ab (as DAMP) or activated microglia (as the
main parameter of NI) is the disease-driving mechan-
ism leading to ND (Okello et al, 2009).
Another DAMP linked to NI is the induction of
heat-shock proteins that can be assessed in vivo
either by reporter systems using heat-shock protein-
sensitive promoter systems (Deckers et al, 2009;
Doubrovin et al, 2011) or by directly targeting probes
such as [18F]fluoromethyldeoxyspergualin (Ghosh
et al, 2011).
Toll-Like Receptors, Receptor for Advanced Glycation
End Products, Adhesion Molecules, Cytokines, and
Chemokines
The past years have witnessed technical advances for
investigating the functional associations of TLRs and
other pattern recognition receptors using noninva-
sive fluorescence imaging methods in living cells
(reviewed by Triantafilou and Triantafilou, 2012).
Independently from imaging, TLRs (e.g., TLR7,8) and
cytokines and chemokines (IL-1b and IL-6) are also
being used as biomarkers for tissue outcome after
stroke (Brea et al, 2011). New TLR-directed therapies
(e.g., anti-TLR antibodies) are now evaluated in
conjunction with imaging methods that assess tissue
outcome (e.g., mMRI after experimental myocardial
infarction; Arslan et al, 2010), or with atomic force
microscopy imaging to investigate the fibrillar mor-
phology of proinflammatory Ab(1 to 42) species
(Udan et al, 2008).
Microglia Cells
Microglial responsiveness to injury places these cells
as diagnostic markers of disease onset or progression
(Perry et al, 2010). As depicted in Figure 1, various
cell surface and mitochondrial receptors expressed
in microglia cells are involved in the regulation and
function of microglia, and some of these receptors
have been used for the development of ligands for
imaging.
Translocator protein: Upregulation of the transloca-
tor protein 18 kDa (TSPO, formerly called peripheral
benzodiazepine receptor or PBR) is a hallmark of
activated microglia. Translocator protein is a protein
of the outer mitochondrial membrane associated
with a voltage-dependent anion channel and a
nucleoside transporter. It is primarily involved in
the transport of cholesterol into mitochondria, which
is the rate-limiting step in the synthesis of steroids
and neurosteroids (Rupprecht et al, 2010). In the
CNS, TSPO is highly expressed in activated micro-
glia, in the choroid plexus and to a lesser extent in
reactive astrocytes, in neurons of the olfactory bulb,
and in neuroblastoma and glioblastoma cell lines
(Rupprecht et al, 2010), but its expression is globally
low in the normal brain. Translocator protein is a
sensitive biomarker for microglial activation and
reactive gliosis (Chauveau et al, 2008), and binding
to TSPO of radiolabeled ligands can be visualized by
PET and SPECT by a variety of ‘old’ ([11C](R)-
PK11195) and ‘novel’ radioligands, such as [11C]
DAA1106, [18F]FE-DAA1106, [11C]DPA-713, [18F]
DPA-714, [18F]PBR28, [18F]PBR111, [11C]SSR18075,
[11C]CLINME, [123I]CLINDE, and [11C]vinpocetine
(Arlicot et al, 2008; Banati et al, 1997; Chauveau
et al, 2008, 2011, 2009; Ciarmiello, 2011; Dolle et al,
2009; Imaizumi et al, 2007; James et al, 2008; Kiferle
et al, 2011; Van Camp et al, 2010; Winkeler et al,
2010). Comparison of ‘novel’ (e.g., [11C]vinpocetine,
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[18F]DPA-714, [18F]PBR111, and [11C]SSR180575)
with ‘old’ ([11C](R)-PK11195) TSPO ligands in rodent
models and patients with NI revealed improved
bioavailability, decreased nonspecific uptake, and
higher specific binding of the novel compounds
(Chauveau et al, 2011, 2009; Van Camp et al, 2010;
Vas et al, 2008). However, different binding affinity
patterns have been identified in humans and should
be taken into account when interpreting the imaging
findings (Owen et al, 2011). Moreover, it has to be
taken into account that various TSPO ligands might
exert different biological effects on microglial activa-
tion with respect to microglia proliferation and
phagocytosis (Choi et al, 2011; Veiga et al, 2007).
Further microglial targets: Further microglial targets
currently being explored for imaging include the
P2X7 receptor (Monif et al, 2009; Yiangou et al, 2006),
the cannabinoid CB2 receptor (Evens et al, 2009;
Horti et al, 2010; Turkman et al, 2011; Vandeputte
et al, 2011), the cyclooxygenase-1 and -2 enzyme
(de Vries et al, 2008; Shukuri et al, 2011), and matrix
metalloproteinases (Iwama et al, 2011; Pinas et al,
2009; Wagner et al, 2007). The CB2 receptors can be
targeted by both radiolabeled and paramagnetic
imaging probes (te Boekhorst et al, 2010).
There is obviously a discrepancy between the
multitude and diversity of cellular and molecular
players in NI on the one side and the relatively small
number of currently established molecular tracers on
the other side. The TSPO (PBR) imaging is a
preferred method of many experimental and clinical
studies and to develop more specific TSPO tracers
may be helpful. Nevertheless, in a way the progress
made for example by DPA-714 as compared with
PK11195 obscures the fact that tracers targeting other
mechanisms are still very rare to date.
Infiltrating Neutrophils, Macrophages, and
T Lymphocytes
The recruitment of circulating leukocytes to the site
of injury is induced by upregulation of endothelial
adhesion molecules (P/E-selectin, intercellular adhe-
sion molecule 1 (ICAM-1), vascular cell adhesion
molecule 1 (VCAM-1); Man et al, 2007). Various
molecular contrast media to target selectin, ICAM,
and VCAM expression have been developed. They
are based, for example, on (1) 125I-labeled gold
nanorods (GdNRs) or 64Cu-labeled nanoparticles
conjugated with anti-ICAM-1 antibody (Rossin
et al, 2008; Shao et al, 2011); (2) GdNRs for
photoacoustic detection (Ha et al, 2011); (3) anti-
CD34 microbubbles as targeted ultrasound contrast
agents (Liu et al, 2011); and anti-ICAM-targeted
echogenic immunoliposomes (Kiessling et al, 2009;
Kim et al, 2010a); (4) anti-VCAM antibody conju-
gated microparticles of iron oxide (Hoyte et al, 2010;
Leung, 2011; McAteer et al, 2007); or (5) double-
conjugated fluorescent microspheres in conjunction
with laser scanning ophthalmoscopy (Sun et al,
2010). Determinations by enzyme-linked immuno-
sorbent assay of soluble E-selectin, ICAM-1, VCAM-
1, together with measurements of matrix metallopro-
teinase-9, tissue inhibitor of metalloproteinase 1,
plasma TNF-a and IL-6, are also used as biomarkers
for NI in association with conventional MRI to
predict tissue injury and stroke severity in early
ischemia (Bogoslovsky et al, 2011).
Studies of the kinetics of T-cell motility and
transmigration by direct cell imaging by dynamic
two-photon microscopy (Soriano et al, 2011; Svens-
son et al, 2010) have revealed a sequential involve-
ment of endothelial ICAM-1 and VCAM-1 in
mediating shear-resistant T-cell arrest, followed by
endothelial ICAM-1 and ICAM-2 mediating T-cell
crawling to sites permissive for diapedesis across
BBB endothelium (Steiner et al, 2010). Sorokin has
pointed out the importance of extracellular matrix
components influencing immune cell infiltration
through the BBB (Sorokin, 2010).
Unspecific labeling of leukocytes or macrophages
is performed ex vivo by incubation of white-blood
cells with 111In- or 99mTc-labeled compounds for
SPECT or [18F]FDG for PET imaging (reviewed by
Wunder et al, 2009), or in vivo using MRI nanosized/
ultrasmall agents such as iron-oxide nanoparticles
(Stuber et al, 2007), liposomes encapsulating mono-
disperse single core superparamagnetic iron-oxide
particles (Soenen et al, 2010) or paramagnetic
lanthanide-based agents (Castelli et al, 2009;
reviewed by Stoll and Bendszus, 2010). The extent
of macrophage labeling in relation to clearance by the
reticulo-endothelial system depends on particle size,
coating, and route of in-vivo delivery. The drawbacks
of unspecific cell labeling methods are the possible
leakage of the label from the cells and unspecific
accumulation in the brain due to a disrupted BBB
(Stoll and Bendszus, 2010; Wunder et al, 2009).
These issues can be overcome by using genetic
engineering of cells expressing artificial marker
genes, in which specific accumulation and trapping
of the label occurs selectively (Costa et al, 2001;
Waerzeggers et al, 2008, 2009). Another approach is
to conjugate a fluorescent probe, such as Cy5.5, by the
HIV-TAT system to T lymphocytes, which are then
adoptively transferred into experimental animals
(Berger et al, 2007). Finally, [18F]FDG mPET/computed
tomography can follow experimental autoimmune
encephalitis (EAE) coinciding with increased glucose
consumption, presumably by infiltrating immune
cells in the spinal cord (Radu et al, 2007).
Alterations of and Within the Blood–Brain Barrier
Changes in the vascular permeability and the BBB can
be assessed by gadolinium-diethylenetriaminepentaa-
cetic acid (Gd-DTPA) and MRI or by 99mTc-pertechne-
tate (99mTeO4) or
99mTe-DTPA and SPECT in vivo
(reviewed by Wunder et al, 2009). Magnetic reso-
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nance imaging with Gd-DTPA is used on a routine
clinical basis to assess the activity and extent of BBB
disruption after ischemic stroke, and during the
disease course of encephalitis, MS, and gliomas, and
it may serve as noninvasive imaging biomarker to
assess the efficiency of treatment with corticosteroids.
Astrocytes and Monoamine Oxidase Type B
Monoamine oxidase type B is an enzyme located at
the outer mitochondrial membrane primarily in
astrocytes and serotoninergic neurons. Monoamine
oxidase type B catalyzes the deamination of mono-
amines, thereby influencing neurotransmitter con-
centrations, and its activity detected with [11C]-L-
deprenyl indicates increased monoamine oxidase
type B content in reactive and proliferating astro-
cytes (Fowler et al, 1987; Gulyas et al, 2011). The
combined assessment of activated microglia and
astrocytes is of special interest, as not only microglia
but also glial fibrillary acidic protein-immunoreac-
tive cells were found to correlate with in-vivo
[11C]PIB binding in postmortem brains of patients
with AD (Kadir et al, 2011). Limited to the experi-
mental setting, transgenic mice carrying the lucifer-
ase gene under control of the glial fibrillary acidic
protein promoter detect reactive astrocytes in vivo
(Cordeau et al, 2008; Luo et al, 2008).
Imaging neuroinflammation in
neurologic diseases
This part summarizes experimental and clinical
neuroimaging studies of NI during the course of
major neurologic diseases, i.e., stroke, MS, AD, PD,
as well as in amyotrophic lateral sclerosis (ALS),
epilepsy, encephalitis, and gliomas.
Stroke: Stroke is the most common neurologic
disorder, the third leading cause of death in the
United States and the leading cause of serious, long-
term disability. In 80% of stroke cases, occlusion of a
cerebral vessel leads to cerebral ischemia and only
immediate establishment of reperfusion can substan-
tially improve functional outcome (NIND, 1995;
Sobesky et al, 2007). Occlusion of a cerebral artery
induces ischemic infarct of the corresponding cere-
bral territory, with a cascade of metabolic and
inflammatory consequences that extend into the
peri-infarct zone (penumbra). Activation of microglia
and astrocytes and recruitment of leukocytes con-
tribute in part to the cell damage (Dirnagl et al, 1999;
Macrez et al, 2011). A retrograde degeneration of
neurons as well as anterograde Wallerian degenera-
tion of axons occurs in cerebral areas distant from the
focal ischemia-induced inflammatory area. This is
accompanied by the activation of microglia along the
degenerating fiber tracts, which may persist for
several years (Perry et al, 2010).
As reviewed recently (Allan et al, 2005; Macrez
et al, 2011; Rivest, 2009; Wang et al, 2007), DAMP-
induced synthesis of proinflammatory cytokines
(TNF-a, IL-1b, and IL-6), microglial activation and
leukocyte infiltration have a major role in the
pathogenic events after cerebral ischemia: cellular
reactions determine the extent of ischemia-induced
tissue damage but are also necessary for tissue repair
and regeneration in the advanced stage. Tumor
necrosis factor-a and IL-1b are rapidly produced in
response to ischemic injury and directly damage
neurons, endothelial and glial cells, and recruit
circulating leukocytes to the site of injury by indu-
cing upregulation of endothelial adhesion molecules
(e.g., P/E-selectin, ICAM-1, and VCAM-1). Cellular
infiltration into the brain, at first of neutrophils and
later of macrophages and lymphocytes (Gelderblom et
al, 2009) contributes to postischemic tissue damage
through activation of nitric oxide synthase and
cyclooxygenase-2 pathways. While gross lymphocyte
infiltration is associated with deleterious effects in
stroke, regulatory T cells seem to have a cerebropro-
tective function by counteracting TNF-a and IFN-g
production (Liesz et al, 2009; Lo, 2009). Microglial
activation triggers phagocytosis of necrotic cells and
secretion of neurotrophic factors (brain-derived neu-
rotrophic factor and insulin-like growth factor;
Madinier et al, 2009). To what extent bone marrow
derived macrophages precursor cells from the blood
can infiltrate the brain and contribute to tissue
damage or repair is still a matter of debate and
further research (Rivest, 2009; Shichita et al, 2009;
Yong and Rivest, 2009). The exact mechanisms that
drive macrophage recruitment to the CNS need to be
further characterized to explore the possibility to
target these cells for therapy. Alternatively, therapeutic
strategies that interfere with DAMP-receptor pathways
(TLRs) might be a promising approach to restrict the
inflammation processes (Macrez et al, 2011).
As many of the mechanisms and pathways
described in stroke pathogenesis may be either
detrimental or beneficial depending on the temporal
disease dynamics, in-vivo imaging of the temporal
profile of key events (e.g., TLR activation, microglial
activation, and lymphocyte infiltration) appears an
important prerequisite for the development and
implementation of new therapeutic paradigms (Fa-
gan et al, 2010). Overall, a better understanding of
the specific roles of inflammatory cells is needed, in
particular with respect to the kinetics of their
recruitment and their relative contribution to the
evolution of stroke (Macrez et al, 2011).
This is particularly important for a more precise
evaluation of the current therapeutic attempts to
modify or alter the poststroke inflammation to
improve the clinical outcome. Whereas imaging in
the acute phase of stroke by computed tomography,
MRI, and PET aims to delineate hypoperfused ‘tissue
at risk’ surrounding the infarcted territory (penum-
bra, mismatch), which is still viable and may be
rescued by therapy (Zaro-Weber et al, 2010), imaging
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at later stages after ischemic stroke targets mostly
ischemia-induced NI. The MRI-based approaches
use systemically administered ultrasmall superpar-
amagnetic iron oxide (USPIO) to track macrophage
infiltration into the ischemic area (Stoll and Bend-
szus, 2010). This approach is however complicated
by passive diffusion of free USPIO through a
defective BBB (Desestret et al, 2009). A myeloperox-
idase-activatable paramagnetic sensor has been de-
veloped and used experimentally to noninvasively
assess leukocyte- and microglia-related myeloperox-
idase activity within the infarct area (Breckwoldt et
al, 2008). Attempts for combined USPIO based with
perfusion-weighted and diffusion-weighted MR ima-
ging in the clinical application are ongoing. The first
studies have revealed conflicting results with regards
to the high variability of extent and distribution of
USPIO enhancement in relation to infarct size and
tissue outcome (Nighoghossian et al, 2007; Stoll and
Bendszus, 2010).
Activated microglia have been the target of a
number of experimental and clinical studies focusing
on studying NI after focal cerebral ischemia. In
experimental models of stroke, activated microglia
revealed by [11C](R)-PK11195 and mPET are located
mainly in the core and in the margin of focal cerebral
ischemia between 4 and 7 days after transient
ischemia (Rojas et al, 2007; Schroeter et al, 2009).
Moreover, activated astrocytes were observed in a rim
surrounding the epicenter of the lesion (Rojas et al,
2007). Using [18F]DPA-714 and mPET imaging in a rat
model of transient ischemia, the time course of TSPO
expression reflecting microglia and macrophage acti-
vation within the first 3 weeks after unilateral middle
cerebral artery occlusion was described (Figure 2).
Expression of TSPO in microglia and macrophages
increased until 7 to 11 days after stroke and decreased
later. In contrast, the centripetal migration of astro-
cytes toward the lesion reflecting formation of a scar
was correlated with TSPO expression in astrocytes at
later times (Martin et al, 2010). Interestingly, minocy-
cline treatment of middle cerebral artery occlusion
rats was able to reduce TSPO expression as shown by
[18F]DPA-714 PET imaging, but this reduction did not
correlate with a reduction in the size of the infarct
(Martin et al, 2011). Interestingly, in a model of
migraine in rats, [11C](R)-PK11195-PET showed TSPO
activation after generation of unilateral cortical
spreading depression, indicating that microglia cells
are activated also in response to a nociceptive
stimulus (Cui et al, 2009).
Expression of TSPO has been imaged using
[11C](R)-PK11195 and PET in relatively small groups
of patients with ischemic stroke (Pappata et al, 2000,
n=7; Gerhard et al, 2005, n=6; Price et al, 2006,
n=4; Radlinska et al, 2009, n=21), or with major risk
factors of stroke (atherosclerosis, hyperlipidemia, and
obesity; Drake et al, 2011, n=4). Between 3 and 150
days after stroke onset, microglia activation reflected
by TSPO ligand uptake can be observed at the
primary lesion site, in peri-infarct regions as well as
in remote locations, and even in the contralateral
hemisphere indicative of pathological changes after
Wallerian degeneration (Gerhard et al, 2005; Radlins-
ka et al, 2009). Based on these results, it has been
suggested that therapeutic targeting of NI may be
extended to late time windows (Price et al, 2006). The
consequences of subcortical stroke lesions with or
without affection of the pyramidal tract were com-
pared in an elegant study by Radlinska et al, (2009)
combining [11C]-(R)-PK11195-PETwith diffusion ten-
sor imaging. A remote activation of microglia was
found only in patients in whom the pyramidal tract
was affected, and this activation was anterograde to
the lesion 2 weeks after stroke. Longer follow-up
times showed that local microglia activity around the
infarct area decreased over time, but that remote
microglial activation along affected pyramidal tracts
persisted at 6 months (Figure 3; Thiel et al, 2010).
The anterograde microglia activity in the brain stem
was linearly related to the extent of pyramidal tract
damage in the early and chronic phase after stroke.
Interestingly, different microglia activation patterns
locally and at distant areas were able to predict
outcome, i.e., the remote inflammatory activity was
positively related to outcome, indicating a possible
neuroprotective role or repair function of microglia
along the tract portions undergoing Wallerian degen-
eration (Thiel et al, 2010). Finally, brain inflamma-
tion was found in patients with a constellation of
chronic systemic inflammatory conditions, even in
the absence of any cerebrovascular event, indicating
that systemic inflammation can drive brain inflam-
mation before stroke in a so-called ‘primed’ inflam-
matory environment (Drake et al, 2011).
Multiple sclerosis: Multiple sclerosis is the most
common inflammatory demyelinating disease of the
CNS with a prevalence ranging between 20 and 150
cases for 100,000 inhabitants. It is pathologically
characterized by inflammation, demyelination, glio-
sis, and axonal injury. T cells and macrophages react
with myelin antigens and initiate an immune
response (secretion of proinflammatory cytokines,
release of toxins, and activation of microglia) that
leads to demyelination and axonal damage.
As has been nicely summarized by Ajami et al
(2011) and reviewed by Kiferle et al (2011), EAE is a
well-studied mouse model of the human disease
characterized by extensive infiltration of the CNS by
inflammatory cells. Initiation of EAE involves the
activation of myelin-specific Th1 or Th17 cells,
which in turn trigger the expansion of resident
microglia and the recruitment of blood-borne myelo-
monocytic cells. The fundamental mechanisms lead-
ing to the distinct stages of relapsing and remitting
disease and to the associated physical impairment
remain controversial (Ajami et al, 2011). Using a
combination of parabiosis and myeloablation to
replace circulating progenitors without affecting
CNS-resident microglia, a strong correlation
was found between monocyte infiltration and
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progression to the paralytic stage of EAE, which can be
blocked by the inhibition of chemokine receptor-
dependent recruitment of monocytes to the CNS
(Ajami et al, 2011). These results point to the essential
and disease-driving function of infiltrating cells in the
pathogenesis of EAE and MS (Ajami et al, 2011).
During early disease, CD4-positive T cells and endo-
genous microglia activation are responsible for disease
initiation before the appearance of functional impair-
ment. It is only the appearance of infiltrating mono-
cytes that correlates with substantial disability,
and impairing the chemokine (C-C motif) receptor
2-dependent recruitment of these cells prevents
progression from very mild to severe disease. The
recruitment and activation of macrophages and micro-
glia have an important role in the removal of damaged
tissue and in the facilitation of neural repair but,
despite their crucial role in host defense, overactivated
microglia induce an excess production of cytotoxic
factors, which enhance and amplify the neuronal
damage (Figure 1; Kiferle et al, 2011). Thus, in EAE,
the infiltration of monocytes appears to represent a
pathogenic overreaction of the innate immune system
(Ajami et al, 2011). Therefore, imaging the passage of
immune cells across the BBB would allow the direct
assessment of the effects of novel therapeutics aiming
to block the transmigration of immune cells into the
CNS for treating CNS-directed autoimmune diseases
(Ajami et al, 2011; Luster et al, 2005).
Various MRI-based techniques can assess disease
activity and effect of therapy in patients with MS.
Conventional T1-weighted Gd-enhanced MRI ad-
dresses acute disease activity and T2-weighted MRI
quantifies overall tissue alterations depicted as
hyperintense lesions (NI and neuroaxonal damage)
(Bakshi et al, 2008; Hayton et al, 2012). Other image-
based primary outcomes in phase II trials of
neuroprotective and reparative strategies in MS are
(1) changes in whole-brain volume to gauge general
cerebral atrophy as measure of neuroaxonal loss;
Figure 2 Time course of microglia activation after experimental ischemia as determined by [18F]DPA-714 and mPET. Panels (A–G)
depict images of different rats showing [18F]DPA-714 accumulation in the ischemic hemisphere at various time points (1 to 30 days
after stroke). Panels (H, I) depict quantitative [18F]DPA-714 accumulation in ischemic (H) versus control (I) hemisphere showing the
peak intensities of microglia activation in the 7 to 15 day after stroke period. (Figure reprinted with permission from Martin et al,
2010.) ID, injected dose; PET, positron-emission tomography.
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(2) T1 hypointensity and magnetization transfer ratio
to monitor the evolution of lesion damage; and (3)
optical coherence tomography findings to evaluate
the anterior visual pathway (Barkhof et al, 2009).
In addition to conventional MR sequences used in
improved model systems (Tourdias et al, 2011),
molecular NI-targeted imaging technologies have
used USPIO particles to image macrophage and T-
cell infiltration in EAE models of MS (Chin et al,
2009; Stoll and Bendszus, 2010). The myeloperox-
idase-activatable paramagnetic sensor mentioned
above has been used to follow T1-weighted signal
increase in areas of active lesions with myeloperox-
idase expression (Chen et al, 2008). More and smaller
lesions are detected by this approach than with
conventional T1- and T2-weighted MRI. Whether
these novel molecular imaging approaches will
translate into clinical applications remains to be
demonstrated. A first attempt in that direction was
reported by Vellinga et al (2008) who showed, in
patients with active MS, that USPIO-enhanced MRI
may reveal subtle inflammatory activity not visible
by conventional MRI and unrelated to Gd-DTPA
enhancement (Figure 4). Similar results were ob-
tained with improved amphiphilic macrocyclic
Gd complexes that allow a more sensitive detection
of BBB changes than Gd-DTPA, indicating that
complementary information is revealed by both
imaging methods (Ladewig et al, 2009; Stoll and
Bendszus, 2010).
Experiments based on genetically engineered T
cells expressing luciferase have shown that autoanti-
gen-specific CD4+ Tcells inhibited inflammation and
promoted immunotherapy in the EAE model (Costa et
al, 2001). Direct visualization of the local interaction
between immune and neuronal cells was shown by
two-photon microscopy in living mice subjected to
EAE (Siffrin et al, 2010; Figure 5). Direct interaction of
Th17 cells specific for myelin/oligodendrocyte glyco-
protein with neuronal cells in demyelinating lesions
was associated with extensive axonal damage. By
combining intravital microscopy with confocal and
electron microscopy it could be excellently shown
that Th17 cells induce severe, localized, and partially
reversible fluctuations in neuronal intracellular Ca2+
concentration as an early sign of neuronal damage,
pointing at the key role of the Th17-cell effector
phenotype for neuronal dysfunction in chronic
inflammation (Siffrin et al, 2010). Moreover, two-
photon microscopy provided local quantification of T-
cell dynamics, tissue infiltration, and interaction in
vivo (Bartholomaus et al, 2009; Kim et al, 2010b;
Siffrin et al, 2010). An excellent review on this topic
has appeared recently (Kawakami and Flugel, 2010).
Microglial activation in patients with MS has been
studied with [11C](R)-PK11195 and PET but so far only
in a limited number of patients (Banati et al, 2000,
n=12; Debruyne et al, 2003, n=22; Vas et al, 2008,
n=4; Versijpt et al, 2005, n=22). Radiotracer binding
was increased in areas of acute and relapse-associated
Figure 4 Cross-sectional patterns of lesion enhancement in patients with multiple sclerosis (MS) as detected by magnetic resonance
imaging (MRI). (A) Pre-Gd T2SE images showing MS lesions. (B) Pre-GdT1-w images showing hypointensity of some of the MS
lesions. (C) Some lesions are Gd-DTPA positive. (D) Post-USPIO images show a Gd-DTPA-positive/USPIO ring-enhancing lesion
(arrow) and a Gd-DTPA-negative/focally USPIO-positive lesion (arrowhead). (Figure reprinted with permission from Vellinga et al,
2008.) USPIO, ultrasmall superparamagnetic iron oxide; Gd-DTPA, gadolinium-diethylenetriaminepentaacetic acid.
Figure 3 Location and extent of microglia activation after focal subcortical ischemia as determined by [11C](R)-PK11195 and HRRT-
PET in conjunction with diffusion tensor imaging (DTI) MRI. Various microglia activation patterns can be observed after focal cerebral
ischemia in humans depending on the affection of the pyramidal tract and the primary lesion size. Acutely activated microglia at the
infarct site that decreases after 6 months (A) are related with good clinical outcome although microglia activation in the brain stem as
sign of anterograde axonal degeneration persists. Lesions that cause a complete transection of the pyramidal tract as determined by DTI
are related to persistent microglia activity at the site of infarction and in the brain stem at 6 months and are related to a poor outcome
(B). In patients where the pyramidal tract is not affected, microglia activation occurs only at the infarct site and not in the brain stem (C).
(Figure reprinted with permission from Thiel et al, 2010.) FA, fractional anisotropy; HRRT, high resolution research tomograph; MRI,
magnetic resonance imaging; PET, positron-emission tomography.
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inflammation detected by Gd-DTPA enhanced T1-
weighted MRI. Interestingly, a significant increase in
[3H](R)-PK11195 or [11C](R)-PK11195 binding on
activated microglia outside the histopathologically
or MRI defined borders of MS plaques was observed
in (1) cerebral central gray-matter areas that are not
normally reported as sites of pathology in MS (Banati
et al, 2000) as well as in (2) normal appearing white
matter (Debruyne et al, 2003). This suggests that
imaging microglial activation in patients with MS
may serve as a complementary biomarker for disease
activity staging. Engineered mouse models show that
the activation of astroglia and microglia may occur
before obvious clinical signs appear in the EAE model
of MS (Luo et al, 2008, 2007). A recent study of
cuprizone-induced NI in C57BL/6 mice showed
positive [123I]-CLINDE accumulation in various brain
regions during the phase of demyelination, and a
decreased uptake during the phase of remyelination
correlating with activated astroglia and microglia cells
(Mattner et al, 2011). Similarly, Abourbeh et al (2012)
have shown that PET imaging with [18F]DPA-714 can
detect the microglial activation in the spinal cord of
EAE-induced rats. In summary, visualizing activated
microglia in gray matter gives TSPO tracers a promis-
ing role in improved understanding of cortical MS
pathologies in humans (Kiferle et al, 2011).
Neurodegeneration: Neurodegenerative diseases,
such as AD, PD, frontotemporal dementia, Hunting-
ton’s disease, and ALS, are the most common chronic
neurologic disorders and they pose an increasing
burden on our aging populations. Alzheimer’s dis-
ease alone affects at least 34 million people world-
wide and its prevalence is expected to triple in the
next decades. In AD, histology shows amyloid-b (Ab)
plaques, neurofibrillary tangles, neuronal loss, and
atrophy. Symptoms of AD are loss of memory,
progressive impairment of cognition, and neuropsy-
chiatric disturbances. In PD, progressive loss of
pigmented dopaminergic neurons in the substantia
nigra and other brain stem nuclei occurs and leads to
dopamine depletion in the striatum, especially in the
putamen. Patients with PD develop motor distur-
bances (bradykinesia, rigidity, tremor, and postural
instability), autonomic dysfunction, cognitive
impairment, and depression. Amyotrophic lateral
sclerosis is the most common motor neuron disease,
Figure 5 Immune infiltrates in demyelinating lesions as depicted by two-photon laser scanning microscopy (TPLSM) are highly
dynamic and show different motility patterns in distinct disease stages. (A) TPLSM of a representative brainstem lesion in the onset of
EAE in B6.tdRFP/B6.Thy1.EGFP (green: EGFP, neuronal processes; red: CD45+ .tdRFP cells) (maximal intensity projection of a
volume of 70mm thickness and 36 planes, time point 0). (B) Automated single-cell tracking of CD45+ .tdRFP cells. (C) TPLSM of a
representative brainstem lesion in the onset of 2d2.tdRFP Th17 cells (red)-induced passive EAE in B6.Rag1/Thy1.EGFP. (D)
Automated single-cell tracking of 2d2.tdRFP Th17 cells. (Figure reprinted with permission from Siffrin et al, 2010).
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affects relatively young patients (B55 years) and has
a projected lifetime risk of 1/2,000. Degeneration of
motor neurons leads to progressive muscle wasting/
weakness, spasticity, and respiratory weakness lead-
ing to death usually within 2 to 5 years. Common to
AD, PD, and ALS, (1) normal life expectancy is
reduced; (2) impairment of cognitive and motor
functions is devastating at the personal and family
level and has major impact on the health-care system;
(3) only symptomatic (not curative) treatment options
are presently available; (4) the impairment of cell’s
protein turnover machinery leads to the deposition of
extracellular and intracellular protein aggregates,
which in turn induce NI with the recruitment of
cells of the immune system (microglia) contributing
to neurotoxicity and degeneration of neurons (Figure
1); (v) diagnosis is based on clinical symptoms
appearing at a late stage in the course of the disease:
in PD, for example, clinical signs appear when over
50% of disease-specific neurons (nigrostriatal projec-
tions) are already damaged.
As reviewed by Rivest (2009), Heneka et al
(2010b), Perry et al (2010), and Glass et al (2010),
in AD, Ab forms extracellular aggregates that activate
microglia through TLRs and receptor for advanced
glycation end products (Figure 1), leading to the
activation of nuclear factor-kB and activator protein
with subsequent production of reactive oxygen
species and release of cytokines (TNF-a, IL-1b, and
IL-6) that stimulate astrocytes, which amplify the
inflammatory/neurotoxic effects. All these events
eventually contribute to neuronal cell death, which
in turn leads to the release of ATP with further
activation of microglial cells through purinergic
P2X7 receptors. However, a- and b-secretases have
nuclear factor-kB binding sites in their promoters,
and the expression of proinflammatory cytokines
appears upregulated in neurons, serving for more
production of Ab in a ‘vicious cycle’ between
inducers, transducers, and effectors. In PD, aggre-
gates of a-synuclein (a-SYN) form intermediate-state
oligomers that, when released from neurons, activate
microglia through TLR-independent mechanisms. In
ALS, aggregates of SOD1 (superoxide dismutase 1)
can induce inflammatory responses by microglia
through TLR2 and CD14 (Glass et al, 2010). However,
some authors have stated that extracellular amyloid
deposits or chronic neurodegeneration on their own
are not able to elicit a robust proinflammatory
response (Perry et al, 2010).
Although microglia activation seems to be induced
in a disease-specific manner, there is a remarkable
convergence in the mechanisms of sensing, trans-
duction, and amplification of the inflammatory
process. It should be pointed out that, while
sustained inflammatory responses involving micro-
glia and astrocytes are likely to contribute to disease
progression, microglia also have a neuroprotective
role by mediating the clearance of Ab (Figure 1).
Therefore, a still unresolved question is how to
control and modulate microglial activity, in a safe
and efficient manner, to slow down or reverse the
course of ND. A better understanding of the brain’s
innate immune response will help to develop
strategies, e.g., based on synthetic TLR agonists, to
selectively activate neuroprotective microglia func-
tions while avoiding detrimental effects on neurons
(Rivest, 2009).
Positron-emission tomography and MRI have con-
tributed a broad spectrum of imaging findings in ND:
(1) altered cerebral glucose consumption (AD); (2)
altered neuronal transmission within the choliner-
gic, dopaminergic, serotonergic, and other neuro-
transmitter systems (AD and PD); (3) accumulation of
Ab and tau proteins (AD and PD); (4) degeneration of
central motor neurons (ALS) (Berti et al, 2011).
Imaging studies of NI in ND have mostly focused
on microglial activation. As pointed out in Figure 1,
Ab deposition elicits a vicious cycle of NI and
neuronal destruction, where microglia have the
central role. Positron-emission tomography with
[11C](R)-PK11195 showed quantitatively the in-vivo
microglial activation involving the entorhinal, tem-
poroparietal, and cingulate cortices (n=8 AD, n=1
MCI, n=6 normal) (Cagnin et al, 2001a). In patients
with frontotemporal dementia, PET showed [11C](R)-
PK11195 binding in the frontal, medial temporal,
and subcortical regions (Cagnin et al, 2004). In APP/
PS1 mice, [3H](R)-PK11195 binding correlated with
the microglial activation determined by immunohis-
tochemistry (Venneti et al, 2009). Kinetic modeling
has shown specific binding potentials (BPs) of
[11C](R)-PK11195 in the human brain (Schuitemaker
et al, 2007) using a simplified reference-tissue model
(Kropholler et al, 2007). The inclusion of an addi-
tional vascular component effectively modelized
disease-specific vascular changes but amplified the
BP more in AD than in controls because of a decrease
in tracer binding to the vasculature in the AD cohort
(Tomasi et al, 2008). It should be pointed out that the
cerebellum as a reference tissue creates problems
because of its proximity to vascular sinuses contain-
ing TSPO. Therefore, several teams are exploring
clustering methods using a database of tissue
kinetics to identify healthy gray-matter voxels that
are used as a reference (Turkheimer et al, 2007). In
double tracer studies of patients with AD using
[11C]PIB together with [11C](R)-PK11195, the distri-
bution of the amyloid load and the microglial
activation were correlated with the cognitive status
(n=13) (Edison et al, 2008). [11C]PIB-PET revealed a
significant twofold increase in the amyloid load in
frontal, temporal, parietal, occipital, and cingulate
cortices, while [11C](R)-PK11195-PET detected sig-
nificant 20% to 35% increases in microglial activa-
tion in the same cortical areas. Importantly, the mini
mental state examination scores in AD patients
correlated with the levels of cortical microglial
activation but not with the amyloid load, supporting
the view that microglia activation is related to
disease activity and progression (Edison et al, 2008)
even at a stage of presymptomatic disease such as
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MCI (Okello et al, 2009; Figure 6). A recent study
explored the relationship between Ab accumulation
and NI in relation to glucose metabolism in patients
with early AD (n=11) (Yokokura et al, 2011). A
negative correlation was found between dementia
score and the [11C](R)-PK11195 BP, but not between
score and [11C]PIB uptake in the limbic, precuneus
and prefrontal regions. Direct comparisons showed a
significant negative correlation between [11C](R)-
PK11195 and [11C]PIB BPs in the posterior cingulate
cortex, the region that manifested the most severe
reduction in [18F]FDG uptake. The lack of coupling
between microglial activation and amyloid deposits
may indicate that Ab accumulation may not always
be the primary cause of microglial activation, but
rather the negative correlation present in the poster-
ior cingulate cortex suggests that microglia can show
higher activation during the production of Ab in
early AD (Yokokura et al, 2011). Considering that
norepinephrine, which is decreased in depression,
has been shown to suppress Ab-induced cytokine
and chemokine production and to increase microglia
migration and phagocytosis of Ab (Heneka et al,
2010a), while antidepressants have been shown to
limit amyloid brain deposition in mice through
decrease in TNF-a (Chavant et al, 2010), it cannot
be excluded that NI could be the missing link
between aging depression and an increased risk of
ND (Frank-Cannon et al, 2009).
Studies in experimental animals and patients with
PD showed that NI, as determined by [11C](R)-
PK11195-PET, is also a significant component of
progressive dopaminergic degeneration (Cicchetti
et al, 2002; Gerhard et al, 2006), even though it
may be difficult to quantify in the clinical situation
(Bartels et al, 2010). Nevertheless, ‘imaging-guided’
drug intervention studies have been initiated, e.g., in
patients with multiple system atrophy focusing on
Figure 6 Early detection of amyloid-b as damage-associated molecular pattern (DAMP) and microglia activation in patients with
mild cognitive impairment by positron-emission tomography (PET). [11C]-(R)-PK11195 binding potentials (BPs) and corresponding
[11C]PIB ratio images in two patients with PIB-positive mild cognitive impairment (MCI). MCI-I has normal PK binding and MCI-II
has increased PK binding suggesting that Ab deposition may be related but also unrelated to microglia activation at very early disease
stages. The detection of microglial activation in patients with MCI suggests that anti-inflammatory therapies may be relevant to the
prevention of AD. (Figure reprinted with permission from Okello et al, 2009.)
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minocycline-induced alterations of microglia activa-
tion in vivo (Dodel et al, 2010).
Microglial activation in ALS has been studied only
in a very limited number of patients (n=10) (Turner
et al, 2004). Increased binding was found in motor
cortex, pons, dorsolateral prefrontal cortex, and
thalamus, and a significant correlation between
binding in the motor cortex and the burden of
clinical upper motor neuron signs was shown
(r=0.73, P=0.009). These findings indicate that
cerebral microglial activation during the evolution
of ALS can be detected in vivo, and support the view
that cerebral pathology is widespread in this disease
(Turner et al, 2004). In an elegant imaging-guided
study by Keller et al, it was shown in the glial
fibrillary acidic protein-luc/SOD1G93A reporter
mouse model of ALS that interfering with microglia
activity by means of minocycline at various disease
stages either ameliorates (at early stages) or enhances
(at later stages) disease activity and symptoms.
Pretreatment with minocycline delayed disease
progression and increased mean survival, whereas
minocycline administered at later stages of disease
was associated with significant alterations in
astrocyte and microglia activation profiles (Keller
et al, 2011). Using another mouse model of ALS
(SOD1G93A) with labeled projection neurons and
labeled microglia/macrophages, in-vivo imaging by
two-photon laser scanning microscopy compared the
role of microglia/macrophage-related NI in the CNS
and peripheral nervous system and showed the
disease-driving role of highly reactive microglia cells
in preclinical disease stages (Dibaj et al, 2011).
Epilepsy: As has been nicely reviewed recently
(Vezzani et al, 2011), glial cells are implicated in a
number of molecular mechanisms of seizure pre-
cipitation and recurrence: (1) alterations in the
phenotype and function of activated microglia and
astrocytes; (2) modifications in potassium and water
channels; (3) alterations of glutamine/glutamate
cycle and glutamate receptor expression; (4) release
of neuromodulatory molecules (gliotransmitters and
neurotrophic factors); and (5) induction of neuroin-
flammatory molecules (cytokines, chemokines, pros-
taglandins, complement factors, and cell adhesion
molecules). This review pointed out that brain injury
and proconvulsant events can activate microglia and
astrocytes to release a number of proinflammatory
mediators initiating a cascade of neuroinflammatory
processes in the brain (Vezzani et al, 2011). So far,
imaging of NI in the context of epilepsy has only
been performed in single patients. [11C]-(R)-PK11195
uptake was observed in regions of epileptic foci and
focal cortical dysplasia as determined by high-
resolution MRI, electroencephalography recording
and intraictal and interictal [18F]FDG-PET (Butler
et al, 2011). These findings confirm results
from invasive studies that revealed a specific and
persistent increase in the numerical density of
activated microglia within dysplastic regions of
patients with epilepsy, and support the view that
the inflammatory response and proinflammatory
molecules contribute to epileptogenicity of focal
cortical dysplasia (Boer et al, 2006).
Encephalitis: T2 and fluid attenuation inversion-
recovery MRI sequences are the imaging methods of
choice for detection with a high sensitivity of single
changes in the temporal lobe caused by HSV-1
infection/reactivation. An enzymatic assay of thymi-
dine kinase of HSV-1 (HSV-1-tk) using radiolabeled
antiviral drugs was proposed 30 years ago for specific
detection of active virus replication in vivo (Saito
et al, 1982). This enzymatic assay was later devel-
oped for imaging transduced gene expression in vivo
and initiated together with other developments the
exciting field of ‘molecular genetic imaging’ (Jacobs
et al, 1999; Tjuvajev et al, 1995), which has been
applied to clinical situations (Jacobs et al, 2001b).
This imaging technology can also assess in-vivo
replication of recombinant HSV-1 vectors in vivo
(Jacobs et al, 2001a).
Apart from approaches to directly image herpes
virus particles in vivo, microglial markers have been
used to quantify herpes encephalitis-induced micro-
glia activation in vivo (Cagnin et al, 2001b; Doorduin
et al, 2010). Similarly to studies in stroke (Figure 3), it
was shown in patients with HSV-1 encephalitis (n=2)
that [11C](R)-PK11195-PET uptake increases signifi-
cantly within the affected limbic system, and addi-
tionally in areas connected to the limbic system by
neural pathways such as the lingual gyrus in the
occipital lobe and the inferior parietal lobe, where
uptake persists for many months ( >12) after antiviral
treatment (Cagnin et al, 2001b). Interestingly, cortical
areas showing an early high [11C](R)-PK11195 binding
subsequently underwent atrophy, underlining the
neurotoxic effects of microglia (Figure 1). It should
be pointed out that, in contrast to HSV-1 encephalitis,
[11C](R)-PK11195-PET studies in patients with human
immunodeficiency virus (HIV) encephalitis were
unable to detect significant activation of microglia in
vivo, indicating that either [11C](R)-PK11195 PET
assessment is insensitive to the degree of macrophage
activation in the HIV-associated minor neurocognitive
impairment, or that macrophage activation is not the
pathological substrate of this neurologic condition
(Wiley et al, 2006). The development of improved
TSPO tracers may give an answer to this question
(Doorduin et al, 2009b; Venneti et al, 2008a,b).
Finally, in an experimental macaque model system,
activated macrophages in lentiviral encephalitis
showed an increase in [3H](R)-PK11195 binding in a
phosphoinositide 3 kinase-dependent manner (Ven-
neti et al, 2007).
Gliomas: Primary neoplasms are the second most
common cause of death from an intracranial disease.
Imaging based on PET and MRI has a crucial role for
diagnosis, therapy guidance and in the recurrent
situation (Dhermain et al, 2010). Whereas PET
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markers for increased amino-acid and nucleoside
metabolism are nowadays used on a regular basis by
many centers, TSPO could also be an exciting target
to study the interrelation between glioma and
microglial cells in vivo (Buck et al, 2011; Takaya
et al, 2007). In patient samples, TSPO suppression in
glioma-infiltrating microglia suggested that TSPO
might have a relevant role in modulating the
antitumor inflammatory response in astrocytic
tumors (Takaya et al, 2007). The expression of TSPO
has been shown in experimental glioma models
and a direct visualization of the location and extent
of the tumor was observed by microPET imaging
with TSPO radiotracers by several groups (Buck et al,
2011; Tang et al, 2012; Winkeler et al, 2012).
Conclusion
Neuroinflammation is a complex orchestrated
response to various stimuli aiming toward tissue
preservation and restoration, which, under patholo-
gical conditions, paradoxically increases tissue
damage and disease activity. In most neurologic
diseases, the neuroinflammatory response deter-
mines tissue outcome. Therefore, a precise and
reliable detection of NI is of great fundamental and
clinical interest. Molecular imaging aims at decipher-
ing the complex interplay of various cellular and
molecular actors of NI in vivo. Presently, its main
applications are the direct visualization of recruit-
ment of specific cells from the periphery into the
brain by two-photon microscopy (e.g., T cells) and
MRI (macrophages) or the activation of microglia by
PETand SPECT imaging. However, the long-term goal
of this research aims to decipher imaging markers for
NI which will guide the therapeutic interventions to
alter the neurotoxic inflammatory cascade, prevent
tissue damage, and enhance tissue repair. One key to
success is the understanding and noninvasive reveal-
ing of the various microglial phenotypes during the
course of diseases, to distinguish ‘neurotoxic’ from
‘neuroprotective’ microglia and to document the
action of treatments inhibiting the former and stimu-
lating the latter for an improved tissue outcome.
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